The ATB200-02 study is an international, multi-center study in adult subjects with Pompe disease. The purpose of this study is to find out whether an investigational co-administration treatment of AT2221 can be safely used with ATB200 and will increase ATB200 in the bloodstream.

The PROPEL study is evaluating the effects of an investigational treatment regimen (AT-GAA co-administration) in adult study participants living with Pompe Disease.

The ZIP Pompe study is an open-label, uncontrolled, multicenter study to evaluate the pharmacokinetics (PK), safety, efficacy, and pharmacodynamics (PD) of Cipaglucosidase Alfa/Miglustat treatment in pediatric participants aged 0 to < 18 years with Late-onset Pompe Disease (LOPD).